1️⃣ Arvinas got approval before it got an owner
FDA approved Veppanu, Arvinas and Pfizer’s vepdegestrant, for ESR1-mutated ER+/HER2- advanced breast cancer after endocrine therapy. It is the first FDA-approved PROTAC.
💡 Why it matters
The approval validates targeted protein degradation in the market, but the asset is narrower than first hoped and still needs a third party to commercialize it.
☕ Coffee talk
How much is a first PROTAC worth if Pfizer and Arvinas still want someone else to sell it?
2️⃣ ARCHIMED is taking Esperion private
ARCHIMED agreed to buy Esperion for up to $1.1B: $3.16 per share in cash, a 58% premium, plus up to $100M in CVRs tied to Nexletol, Nexlizet and Enbumyst sales.
💡 Why it matters
This is private capital buying commercial cardiometabolic execution, not a binary R&D story. The CVR leaves product-performance risk with sellers.
☕ Coffee talk
Is this an exit, or just public markets admitting they do not want to own small-cap cardio sales curves?
3️⃣ Sun bought global pharma scale, not a pipeline
Sun Pharma agreed to acquire Organon for $14 per share in cash, valuing the company at $11.75B EV. Organon brings more than 70 women’s health and general medicines, including biosimilars, across 140 countries.
💡 Why it matters
The largest biopharma deal of 2026 so far is about mature brands, biosimilars and global cash flow. That is a different buyer logic from the usual clinical-stage biotech premium.
☕ Coffee talk
Who else looks at old Merck-style global brands and decides the boring cash flow is the asset?